
    
      The patients with autoantibody to IFN-Î³ and past or current history of proven opportunistic
      infection will receive 2 treatment cycles of bortezomib subcutaneously (4 injections of 1.3
      mg Bortezomib /m2 body surface per cycle), followed by low dose oral cyclophosphamide for 4
      month after completion treatment with bortezomib.
    
  